Noven Tries To Block Watson's Generic Daytrana
Noven said in a statement that it had filed a complaint in New Jersey federal court alleging Watson had filed an abbreviated new drug application with the U.S. Food and Drug Administration to make generic versions of Daytrana, violating Noven's patents.
The patents are valid until 2018, according to the statement.
“The lawsuit reflects...
To view the full article, register now.